Webinar Description
To advance research for precision oncology, it is essential to identify molecular changes that underly tumorigenesis. Now you can tailor tumor genomic profiling assays by customizing next-generation sequencing (NGS) cancer panels to fit your laboratory’s specific requirements, including the assessment of new and emerging biomarkers, the immuno-oncology biomarkers (tumor mutational burden (TMB) and microsatellite instability (MSI)), and homologous recombination deficiency (HRD). Agilent SureDesign, a user-friendly panel design software powered by machine learning, offers fast and easy design of Agilent SureSelect Cancer Custom panels to enable detection of key classes of somatic alterations. In this webinar, you will learn about:

Director, R&D, Agilent Technologies
Mike is the director of NGS content development at Agilent Technologies. He and his team are responsible for assay development using SureSelect NGS target enrichment technology.

Field Applications Scientist, Agilent Technologies
Danielle is a member of Agilent’s European custom design service. This team assists customers by creating custom NGS target enrichment panels as well as CGH and GE microarrays designs.
For research use only. Not for use in diagnostic procedures.
PR7001-2614